Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP

J M De Klerk; B A Zonnenberg; G H Blijham; A D Van Het Schip; A Hoekstra; S H Han; J M Quirijnen; A Van Dijk; P P Van Rijk

Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP

Anticancer Res. 1997 May-Jun;17(3B):1773-7.

Authors

J M De Klerk¹, B A Zonnenberg, G H Blijham, A D Van Het Schip, A Hoekstra, S H Han, J M Quirijnen, A Van Dijk, P P Van Rijk

Affiliation

¹ Department of Nuclear Medicine, University Hospital Utrecht, The Netherlands.

PMID: 9179233

Abstract

Recent advances in radionuclide therapy offer a new approach for the management of metastatic bone pain. This paper reports the results of dosage escalation studies with 186Re-HEDP as a bone-seeking radiopharmaceutical in patients with bone metastases originating from breast or prostate cancer with regard to toxicity, pharmacokinetics and bone marrow dosimetry and the palliating effect on bone pain. Thrombocytopenia proved to be the dose limiting factor and 186Re-HEDP showed a considerable efficacy in end-stage patients with metastatic bone pain.

Publication types

Review

MeSH terms

Bone Neoplasms / physiopathology
Bone Neoplasms / radiotherapy*
Bone Neoplasms / secondary*
Breast Neoplasms / physiopathology
Breast Neoplasms / radiotherapy*
Etidronic Acid / adverse effects
Etidronic Acid / pharmacokinetics
Etidronic Acid / therapeutic use*
Female
Humans
Male
Organometallic Compounds
Pain, Intractable*
Prostate-Specific Antigen / blood
Prostatic Neoplasms / physiopathology
Prostatic Neoplasms / radiotherapy*
Radiopharmaceuticals
Rhenium / adverse effects
Rhenium / pharmacokinetics
Rhenium / therapeutic use*
Thrombocytopenia / etiology

Substances

Organometallic Compounds
Radiopharmaceuticals
rhenium-186 HEDP
Rhenium
Prostate-Specific Antigen
Etidronic Acid